Cited by 369SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Researchvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Open access

Seydoux, Emilie, Homad, Leah J., MacCamy, Anna J., Parks, K. Rachael, Hurlburt, Nicholas K., Jennewein, Madeleine F., Akins, Nicholas R., Stuart, Andrew B., Wan, Yu-Hsin, Feng, Junli, Whaley, Rachael E., Singh, Suruchi, Boeckh, Michael, Cohen, Kristen W., McElrath, M. Juliana, Englund, Janet A., Chu, Helen Y., Pancera, Marie, McGuire, Andrew T., Stamatatos, Leonidas·2020·Immunity

DOI 10.1016/j.immuni.2020.06.001PMC PMC7276322

Open this paper in CoChat — free account Open PDF

Abstract

Antibody responses develop following SARS-CoV-2 infection, but little is known about their epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We isolated B cells specific for the SARS-CoV-2 envelope glycoprotein spike (S) from a COVID-19-infected subject 21 days after the onset of clinical disease. 45 S-specific monoclonal antibodies were generated. They had undergone minimal somatic mutation with limited clonal expansion, and three bound the receptor-binding domain (RBD). Two antibodies neutralized SARS-CoV-2. The most potent antibody bound the RBD and prevented binding to the ACE2 receptor, while the other bound outside the RBD. Thus, most anti-S antibodies that were generated in this patient during the first weeks of COVID-19 infection were non-neutralizing and target epitopes outside the RBD. Antibodies that disrupt the SARS-CoV-2 S-ACE2 interaction can potently neutralize the virus without undergoing extensive maturation. Such antibodies have potential preventive and/or therapeutic potential and can serve as templates for vaccine design.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2020.06.001

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048 · cited 1×
“5 million documented cases of COVID-19 and over 420,000 deaths (Dong et al., 2020).”
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · cited 10×
“, 2020), and immunization with SARS S protein can elicit anti-SARS-CoV-2 neutralizing antibodies in wild-type and humanized mice, as well as llamas (Walls et al., 2020; Wang et al., 2020;Wrapp et al., 2020).”
BackgroundMethodResultInfluential
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Self-citation
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · cited 1×
“Like SARS-CoV, SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as an entry receptor binding with nM affinity (Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020; Hoffmann et al., 2020; Letko et al., 2020; Ou et al., 2020).”
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 4×
“Although SARSCoV and SARS-CoV-2 share extensive amino acid sequence in the RBD (74%), and both viruses utilize human ACE2 for entry, the amino acid identity in the receptor binding motif is only 50% (Wan et al., 2020).”
InfluentialSelf-citation
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · cited 1×
“Like SARS-CoV, SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as an entry receptor binding with nM affinity (Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020; Hoffmann et al., 2020; Letko et al., 2020; Ou et al., 2020).”
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097 · cited 2×
“Like SARS-CoV, SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as an entry receptor binding with nM affinity (Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020; Hoffmann et al., 2020; Letko et al., 2020; Ou et al., 2020).”
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614 · cited 3×
“Although binding and neutralizing antibody responses are known to develop following SARS-CoV-2 infection (Ni et al., 2020; Okba et al., 2020), no information is currently available on the epitope specificities, clonality, binding affinities, and neutralizing potentials of the antibody response.”
BackgroundResultInfluential

Flagged first, then by citations

Show all 44 references

1 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 369

The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition
Hattori, T., Koide, A., Noval, M. G., Panchenko, T., Romero, L. A., Teng, K. W., Tada, T., Landau, N. R., Stapleford, K. A., & Koide, S. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.166748 · Cited by 20
“The structure and conformational dynamics of the spike protein offer possible mechanistic basis for the low immunogenicity of the RBD.”
Influential
SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over timePreprint
Vaisman‐Mentesh, A., Dror, Y., Tur‐Kaspa, R., Markovitch, D., Kournos, T., Dicker, D., & Wine, Y. (2020) · medRxiv · doi:10.1101/2020.08.23.20179796 · Cited by 20
Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months
Serwanga, J., Ankunda, V., Sembera, J., Kato, L., Oluka, G. K., Baine, C., Odoch, G., Kayiwa, J. T., Auma, B. O., Jjuuko, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152522 · Cited by 20
A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection
Adams, L. J., VanBlargan, L. A., Liu, Z., Gilchuk, P., Zhao, H., Chen, R. E., Raju, S., Chong, Z., Whitener, B. M., Shrihari, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101305 · Cited by 18
Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients
Benning, L., Klein, K., Morath, C. P., Bartenschlager, M., Kim, H., Buylaert, M., Reineke, M., Töllner, M., Nußhag, C., Kälble, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840136 · Cited by 18
Association between self-reported signs and symptoms and SARS-CoV-2 antibody detection in UK key workers
Mulchandani, R., Taylor-Philips, S., Jones, H. E., Ades, A. E., Borrow, R., Linley, E., Kirwan, P., Stewart, R., Moore, P., Boyes, J., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.019 · Cited by 18
SARS‐CoV‐2 sculpts the immune system to induce sustained virus‐specific naïve‐like and memory B‐cell responses
de Campos‐Mata, L., Vaquero, S. T., Tachó‐Piñot, R., Piñero, J., Grasset, E. K., Arrieta‐Aldea, I., Melero, N. R., Carolis, C., Horcajada, J. P., Cerutti, A., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1339 · Cited by 17
“The median length of stay from hospitalization to discharge was 16 days [5-90].”
Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago
Qiang, M., Ma, P., Li, Y., Liu, H., Harding, A. C., Min, C., Wang, F., Liu, L., Yuan, M., Ji, Q., et al. (2021) · Advanced Science · doi:10.1002/advs.202102181 · Cited by 20
RETRACTED: Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19
Mustapha, J. O., Abdullahi, I. N., Ajagbe, O., Emeribe, A. U., Fasogbon, S. A., Onoja, S. O., Ugwu, C. E., Umeozuru, C. M., Ajayi, F. O., Tanko, W. N., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e05951 · Cited by 17
Retracted
Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America
Quinonez, E., Vahed, M., Shahraki, A. H., & Mirsaeidi, M. S. (2021) · Viruses · doi:10.3390/v13050930 · Cited by 16
“The neutralizing monoclonal CV30 antibody was isolated from a patient infected with SARS-CoV-2, in complex with the receptor S-RBD [28].”
Background
Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
Aiello, A., Grossi, A., Meschi, S., Meledandri, M., Vanini, V., Petrone, L., Casetti, R., Cuzzi, G., Salmi, A., Altera, A. M. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920227 · Cited by 18
“Pool M responders [N (% among positive Tcell responders)] 1 (25) 2 (100) 3(50) 4 (57.”
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
Chao, C. W., Sprouse, K. R., Miranda, M. C., Catanzaro, N., Hubbard, M. L., Addetia, A., Stewart, C., Brown, J. T., Dosey, A. M., Valdez, A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115036 · Cited by 18
Self-citation
Overcoming the limitations of COVID-19 diagnostics with nanostructures, nucleic acid engineering, and additive manufacturing
Li, N., Zhao, B., Stavins, R. A., Peinetti, A. S., Chauhan, N., Bashir, R., Cunningham, B. T., King, W. P., Lu, Y., Wang, X., et al. (2021) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2021.100966 · Cited by 17
A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts
Schultz, M. D., Suschak, J. J., Botta, D., Silva-Sánchez, A., King, R. G., Detchemendy, T. W., Meshram, C. D., Foote, J. B., Zhou, F., Tipper, J. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2127292 · Cited by 16
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in micePreprint
Cohen, A. A., Gnanapragasam, P. N. P., Lee, Y. E., Hoffman, P. R., Ou, S., Kakutani, L. M., Keeffe, J. R., Wu, H.-J., Howarth, M. R., West, A. P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.17.387092 · Cited by 19
“Consistent with its function in viral entry, S is the primary target of neutralizing antibodies (13-22), with many targeting the RBD (14-18, 21-26).”
Evolutionary trajectory of SARS-CoV-2 genome shifts during widespread vaccination and emergence of Omicron variant
Gayvert, K. M., McKay, S., Lim, W. K., Baum, A., Kyratsous, C. A., Copin, R., & Atwal, G. S. (2023) · npj Viruses · doi:10.1038/s44298-023-00007-z · Cited by 17
Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern
Rubio, A. A., Baharani, V. A., Dadonaite, B., Parada, M., Abernathy, M. E., Wang, Z., Lee, Y. E., Eso, M. R., Phung, J. L., Ramos, I., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq5720 · Cited by 21
Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy
Cheng, Z. J., Li, B., Zhan, Z., Zhao, Z., Xue, M., Zheng, P., Lyu, J., Hu, C., He, J., Chen, R., et al. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08912-y · Cited by 15
Advances in antibody discovery from human BCR repertoires
Xu, Z., Ismanto, H. S., Zhou, H., Saputri, D. S., Sugihara, F., & Standley, D. M. (2022) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2022.1044975 · Cited by 18
Frequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibody responses
Pushparaj, P., Nicoletto, A., Dopico, X. C., Sheward, D. J., Kim, S., Ekström, S., Murrell, B., Corcoran, M., & Hedestam, G. B. K. (2023) · Frontiers in Virology · doi:10.3389/fviro.2023.1128253 · Cited by 16
“Several antibodies that use these genes bind and neutralize the virus even in their germline state, suggesting a role for the germline-encoded residues in epitope binding (17).”
Background
Deciphering Fc-effector functions against SARS-CoV-2
Beaudoin-Bussières, G., & Finzi, A. (2024) · Trends in Microbiology · doi:10.1016/j.tim.2024.01.005 · Cited by 19
Rapid and cost‐effective process based on insect larvae for scale‐up production of SARS‐COV‐2 spike protein for serological COVID‐19 testing
Smith, I., Callum, G. J. M., Sabljic, A. V., Marfía, J. I., Bombicino, S. S., Trabucchi, A., Iacono, R. F., Birenbaum, J. M., Vázquez, S., Minoia, J. M., et al. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27889 · Cited by 15
SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity
Olia, A. S., Tsybovsky, Y., Chen, S. J., Liu, C., Nazzari, A. F., Ou, L., Wang, L., Kong, W., Leung, K., Liu, T. W. B., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101127 · Cited by 14
New insights into human immune memory from SARS‐CoV ‐2 infection and vaccination
Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Allergy · doi:10.1111/all.15502 · Cited by 15
[Retracted] Computational Study on the Inhibitory Effect of Natural Compounds against the SARS‐CoV‐2 Proteins
Jayaraj, J. M., Jothimani, M., Palanisamy, C. P., Pentikäinen, O. T., Pannipara, M., Al-Sehemi, A. G., Muthusamy, K., & Gopinath, K. (2022) · Bioinorganic Chemistry and Applications · doi:10.1155/2022/8635054 · Cited by 14
“civet cats, swine, cats, ferrets, nonhuman primates (NHPs), and humans as a receptor [4, 5].”
Background
Retracted
The role of inflammatory gene polymorphisms in severe COVID-19: a review
Yip, J. Q., Oo, A., Ng, Y. L., Chin, K. L., Tan, K., Chu, J. J. H., AbuBakar, S., & Zainal, N. (2024) · Virology Journal · doi:10.1186/s12985-024-02597-3 · Cited by 15
The development of neutralizing antibodies against SARS-CoV-2 and their common features
Liu, L. D., Lian, C., Yeap, L.-S., & Meng, F. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa070 · Cited by 14
“CV30, which shows only 2-amino acid difference from the germline sequence have increased binding affinity by 100-fold (Hurlburt et al., 2020).”
BackgroundInfluential
Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies
Whaley, R. E., Ameny, S., Arkatkar, T., Seese, A. M., Wall, A., Khan, I., Carter, J. J., Scherer, E. M., Rawlings, D. J., Galloway, D. A., et al. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112901 · Cited by 14
“Importantly, the rapid isolation of mAbs is a powerful method that can be used to understand the human immune response to infection in the context of rapidly emerging infections, such as the current COVID-19 pandemic (Pinto et al., 2020; Traggiai et al., 2004; Seydoux et al., 2020; Ju et al., 2020; Shi et al., 2020).”
Self-citation
How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika
Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Jette, C. A., & Björkman, P. J. (2021) · Viruses · doi:10.3390/v13102106 · Cited by 12
Harnessing immunoinformatics for developing a multiple-epitope peptide-based vaccination approach against SARS-CoV-2 spike protein
Moustafa, R. I., Faraag, A. H. I., El‐Shenawy, R., Agwa, M. M., & Elsayed, H. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103661 · Cited by 14
“…were discovered in the sera of COVID-19 convalescent individuals (Ni et al., 2020), and antibodies targeting the S-protein, isolated from SARS-CoV-2 diseased patients, exhibited neutralizing potency and hence might be protective against reinfection (Seydoux et al., 2020; Suthar et al., 2020).”
Central tolerance shapes the neutralizing B cell repertoire against a persisting virus in its natural host
Florova, M., Abreu-Mota, T., Paesen, G. C., Beetschen, A. S., Cornille, K., Marx, A., Narr, K., Sahin, M., Dimitrova, M., Swarnalekha, N., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318657121 · Cited by 13
Are SARS‐CoV‐2 IgA antibodies in paediatric patients with chilblain‐like lesions indicative of COVID‐19 asymptomatic or paucisymptomatic infection?
Diociaiuti, A., Giancristoforo, S., Terreri, S., Corbeddu, M., Concato, C., Atti, M. L. C. D., Zambruno, G., Carsetti, R., & Hachem, M. E. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16934 · Cited by 12
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2
Ilinykh, P. A., Periasamy, S., Huang, K., Kuzmina, N. A., Ramanathan, P., Meyer, M. N., Mire, C. E., Kuzmin, I. V., Bharaj, P., Endsley, J. R., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00471-3 · Cited by 14
Epitope mapping of neutralising anti‐SARS‐CoV‐2 monoclonal antibodies: Implications for immunotherapy and vaccine design
Ghotloo, S., Maghsood, F., Golsaz‐Shirazi, F., Amiri, M. M., Moog, C., & Shokri, F. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2347 · Cited by 13
Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Chiang, H.-L., Liang, K.-H., Lu, R., Kuo, T.-W., Lin, Y., & Wu, H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00955-x · Cited by 12
“Typically, the RBD-specific neutralizing antibodies isolated during early convalescence exhibit very limited or even no SHM [22, 30, 37, 53].”
BackgroundInfluential
Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual
Guerra, D., Beaumont, T., Radić, L., Kerster, G., van der Straten, K., Yuan, M., Torres, J. L., Lee, W.-H., Liu, H., Poniman, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108009 · Cited by 13
Potent NTD-Targeting Neutralizing Antibodies against SARS-CoV-2 Selected from a Synthetic Immune System
Li, W., Wang, F., Li, Y., Yan, L., Liu, L., Zhu, W., Ma, P., Shi, X., & Yang, G. (2023) · Vaccines · doi:10.3390/vaccines11040771 · Cited by 11
Common low complexity regions for SARS-CoV-2 and human proteomes as potential multidirectional risk factor in vaccine development
Gruca, A., Ziemska-Legięcka, J., Jarnot, P., Sarnowska, E. A., Sarnowski, T. J., & Grynberg, M. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04017-7 · Cited by 11
Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines
Diamanti, A. P., Rosado, M. M., Nicastri, E., Sesti, G., Pioli, C., & Laganà, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708848 · Cited by 11
A Novel Mathematical Model That Predicts the Protection Time of SARS-CoV-2 Antibodies
Xu, Z., Wei, D., Zhang, H., & Jacques Demongeot, A. (2023) · Viruses · doi:10.3390/v15020586 · Cited by 12
Validation of Ligand Tetramers for the Detection of Antigen-Specific Lymphocytes
Fitzpatrick, K. S., Degefu, H. N., Poljakov, K., Bibby, M. G., Remington, A. J., Searles, T. G., Gray, M. D., Boonyaratanakornkit, J. B., Rosato, P. C., & Taylor, J. J. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200934 · Cited by 12
An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 micePreprint
Beaudoin-Bussières, G., Chen, Y.-Z., Ullah, I., Prévost, J., Tolbert, W., Symmes, K., Ding, S.-L., Benlarbi, M., Gong, S., Tauzin, A., et al. (2021) · bioRxiv · doi:10.1101/2021.09.08.459408 · Cited by 15
Self-citation
Deep immunoglobulin repertoire sequencing depicts a comprehensive atlas of spike-specific antibody lineages shared among COVID-19 convalescents
Yan, Q., Zhang, Y., Hou, R., Pan, W., Liang, H., Gao, X., Deng, W., Huang, X., Qu, L., Tang, C., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2290841 · Cited by 9
“The most common clonotype cl.142, and two other clonotypes cl.143 and cl.144, encoded by IGHV3-30, are S2-targeting non-neutralizing antibody lineages [34] (Figure 4A and C; Figure S6).”
Background
COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research
Mendoza, P., Lorenzi, J. C. C., & Gaebler, C. (2020) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000657 · Cited by 10
No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults
Ercanoglu, M. S., Gieselmann, L., Dähling, S., Poopalasingam, N., Detmer, S., Koch, M., Korenkov, M., Halwe, S., Klüver, M., Cristanziano, V. D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103951 · Cited by 9
Detection of SARS‐CoV‐2‐specific memory B cells to delineate long‐term COVID‐19 immunity
Thieme, C. J., Abou‐El‐Enein, M., Fritsche, E., Anft, M., Paniskaki, K., Skrzypczyk, S., Doevelaar, A., Elsallab, M., Brindle, N. R., Blazquez‐Navarro, A., et al. (2021) · Allergy · doi:10.1111/all.14827 · Cited by 10
Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins
Leach, A., Miller, A., Bentley, E. M., Mattiuzzo, G., Thomas, J. C., McAndrew, C., van Montfort, R., & Rabbitts, T. H. (2021) · Scientific Reports · doi:10.1038/s41598-021-89887-w · Cited by 11
Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
Sulbarán, G., Maisonnasse, P., Amen, A., Effantin, G., Guilligay, D., Dereuddre‐Bosquet, N., Burger, J. A., Poniman, M., Grobben, M., Buisson, M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100528 · Cited by 11
But does it work? Improving evaluations of sexuality education.
Haffner, D. W., & Goldfarb, E. S. (1997) · PubMed · Cited by 10
SARS-CoV-2 infection induces germinal center responses with robust stimulation of CD4 T follicular helper cells in rhesus macaquesPreprint
Elizaldi, S. R., Lakshmanappa, Y. S., Roh, J. W., Schmidt, B., Carroll, T. D., Weaver, K. D., Smith, J. C., Deere, J., Dutra, J. C., Stone, M., et al. (2020) · bioRxiv · doi:10.1101/2020.07.07.191007 · Cited by 10
Ultra-high-throughput IGH genotyping of 25 global populations reveals population-biased allelic diversity and homozygous V and D gene deletions
Corcoran, M., Narang, S., Kaduk, M., Chernyshev, M., Färnert, A., Sundling, C., & Hedestam, G. B. K. (2026) · Immunity · doi:10.1016/j.immuni.2026.01.026 · Cited by 10
Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies
Inada, M., Ishikane, M., Terada, M., Matsunaga, A., Maeda, K., Tsuchiya, K., Miura, K., Sairenji, Y., Kinoshita, N., Ujiie, M., et al. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.04.017 · Cited by 9
Validation of a Novel Fluorescent Lateral Flow Assay for Rapid Qualitative and Quantitative Assessment of Total Anti-SARS-CoV-2 S-RBD Binding Antibody Units (BAU) from Plasma or Fingerstick Whole-Blood of COVID-19 Vaccinees
Younes, N., Al‐Sadeq, D. W., Shurrab, F. M., Zedan, H. T., Abou-Saleh, H., Halawa, B. Y. A., AlHamaydeh, F. M., Elsharafi, A. E., Daas, H. I., Thomas, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10081318 · Cited by 9
Antibodies, epicenter of SARS-CoV-2 immunology
Pecetta, S., Pizza, M., Sala, C., Andreano, E., Pileri, P., Troisi, M., Pantano, E., Manganaro, N., & Rappuoli, R. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00711-w · Cited by 9
“These observations are supported by studies that investigated the DNA sequences of the genes encoding the circulating antibodies and showed that neutralizing antibodies are only few mutations distant from their respective germline sequence, suggesting absence of affinity maturation in germinal centers and low capacity…”
INFECTION-ACQUIRED VERSUS VACCINE-INDUCED IMMUNITY AGAINST COVID-19
Velikova, T. V. (2021) · Central Asian Journal of Medical Hypotheses and Ethics · doi:10.47316/cajmhe.2021.2.1.05 · Cited by 9
Antibody Display of cell surface receptor Tetraspanin12 and SARS-CoV-2 spike proteinPreprint
Hsieh, F.-L., & Chang, T.-H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.29.446300 · Cited by 9
Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS‐CoV‐2 Vaccine and the Resultant Neutralization Activity
Wang, J., Ni, S., Chen, Q., Wang, C., Liu, H., Huang, L., Nasir, M. W., Wang, W. J., Zhang, X., Wu, J., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.70073 · Cited by 8
“Other germlines, such as IGHV1 ‐ 69 [43, 44] and IGHV3 ‐ 30 [43], also generate antibodies that recognize different viral components.”
The immunological impact of revaccination in a hybrid-immune world
Bausch-Jurken, M. T., & Alter, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1588259 · Cited by 11
Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants
Shitaoka, K., Higashiura, A., Kawano, Y., Yamamoto, A., Mizoguchi, Y., Hashiguchi, T., Nishimichi, N., Huang, S., Ito, A., Ohki, S., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04782-6 · Cited by 9
RISK-TAKING BEHAVIOR IN RECOVERED COVID-19 PATIENTS
EGELİ, A., Adıgüzel, S., Kapıcı, Y., Güc, B., Tekin, A. Y., Private Psychological Counselor, A., & Tekın, A. (2021) · Psychiatria Danubina · doi:10.24869/psyd.2021.107 · Cited by 7
“Moreover, some studies have shown recovered patients produce antibodies and this may lead them to a favorable position in a reinfection circumstance (Ni et al. 2020, Seydoux et al. 2020).”
Background
Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy
Zhu, X., Yu, F., Wu, Y., & Ying, T. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab008 · Cited by 8
“[64] isolated 45 S-specific mAbs from a COVID-19-infected individual 21 days post the onset of clinical disease.”
Background
Longevity of memory B cells and antibodies, as well as the polarization of effector memory helper T cells, are associated with disease severity in patients with COVID-19 in Bangladesh
Akhtar, M., Basher, S. R., Nizam, N. N., Kamruzzaman, M., Khaton, F., Banna, H. A., Kaisar, M. H., Karmakar, P. C., Hakim, A., Akter, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1052374 · Cited by 8
Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ SubjectsPreprint
Jennewein, M. F., MacCamy, A. J., Akins, N. R., Feng, J., Homad, L. J., Hurlburt, N. K., Seydoux, E., Wan, Y.-H., Stuart, A. B., Edara, V. V., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.23.436684 · Cited by 9
Self-citation
Amino acids 484 and 494 of SARS-CoV-2 spike are hotspots of immune evasion affecting antibody but not ACE2 bindingPreprint
Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.22.441007 · Cited by 8
Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine EscapePreprint
Rochman, N. D., Faure, G., Wolf, Y. I., Freddolino, P. L., Zhang, F., & Koonin, E. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.30.458225 · Cited by 8
Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal modelsPreprint
Cohen, A. A., van Doremalen, N., Greaney, A. J., Andersen, H., Sharma, A., Starr, T. N., Keeffe, J., Fan, C.-H., Schulz, J. E., Gnanapragasam, P. N. P., et al. (2022) · bioRxiv · doi:10.1101/2022.03.25.485875 · Cited by 5
“Many of the most potent neutralizing antibodies against SARS-2 block binding ACE2 to the RBD (16-20, 23-29), and RBD targeting”
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Wang, Z., Shi, Z., Liao, X., Quan, G., Dong, H., Zhao, P., Zhou, Y., Shi, N., Wang, J., Wu, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202402975 · Cited by 8
Self-citation
Homologous and heterologous serological response to the N‐terminal domain of SARS‐CoV‐2 in humans and mice
Lv, H., Tsang, O. T., So, R. T. Y., Wang, Y., Yuan, M., Liu, H., Yip, G. K., Teo, Q. W., Lin, Y., Liang, W., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149234 · Cited by 6
Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase
Sokullu, E., Pinard, M., Gauthier, M., & Coulombe, B. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1909566 · Cited by 7
Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants
Ueno, M., Iwata‐Yoshikawa, N., Matsunaga, A., Okamura, T., Saito, S., Ashida, S., Yoshida, I., Nagashima, M., Asakura, H., Yaoita, Y., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105297 · Cited by 7
“Potent RBD-specific antibodies have been isolated from many convalescent donors (Brouwer et al., 2020; Cao et al., 2020; Chen et al., 2020; Chi et al., 2020; Hansen et al., 2020; Ju et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Shi et al., 2020; Wec et al., 2020; Wu et al., 2020b; Zos…”
Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19
Bartlett, M. L., Suwanmanee, S., Akindele, N. P., Ghimire, S., Chan, A. K. P., Guo, C., Gould, S. J., Cox, A. L., & Griffin, D. E. (2022) · Viral Immunology · doi:10.1089/vim.2021.0191 · Cited by 7
“Despite a lack of germinal center processing and somatic hypermutation for these ASCs, previous studies have shown that the rapid S-speciﬁc response includes cells producing potent virus neutralizing antibody likely to be important for early virus control (41,72).”
VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
Kulemzin, S. V., Sergeeva, M. V., Baranov, K. O., Gorchakov, A. A., Guselnikov, S. V., Николаевна, Б. Т., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Danilenko, D., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060895 · Cited by 7
“Recombinant CV30 was produced in-house based on the published sequences [14].”
MethodInfluential
Effects of Prior Infection with SARS-CoV-2 on B Cell Receptor Repertoire Response during Vaccination
Fraley, E., Khanal, S., Pierce, S. H., LeMaster, C., McLennan, R., Pastinen, T., & Bradley, T. (2022) · Vaccines · doi:10.3390/vaccines10091477 · Cited by 8
“, no mutations) have been observed early in naïve response to SARS-CoV-2 infection [31].”
Background
SARS-CoV-2 Seroprevalence among Health Care Workers—A Voluntary Screening Study in a Regional Medical Center in Southern Germany
Müller, K., Girl, P., Ruhnke, M., Spranger, M., Kaier, K., von Buttlar, H., Dobler, G., & Borde, J. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18083910 · Cited by 7
Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades agoPreprint
Qiang, M., Ma, P., Li, Y., Liu, H., Harding, A. C., Min, C., Liu, L., Yuan, M., Ji, Q., Tao, P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.06.370676 · Cited by 7
“CoV-2 convalescent patients contain only a few amino-acid mutations (3, 8, 9, 36, 37).”
Background
Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 InfectionPreprint
Haddad, N. S., Nguyen, D. C., Kuruvilla, M. E., Morrison-Porter, A., Anam, F. A., Cashman, K. S., Ramonell, R. P., Kyu, S. Y., Saini, A. S., Cabrera-Mora, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.04.410589 · Cited by 7
Regulators and Conductors of Immunity: Natural Immune System in Health and Autoimmunity
Böröcz, K., Szinger, D., Simon, D., Berki, T., & Németh, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115413 · Cited by 9
Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses
Chuang, G., Shen, C., Cheung, C. S., Gorman, J., Creanga, A., Joyce, M. G., Leung, K., Rawi, R., Wang, L., Yang, E. S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662909 · Cited by 6
The characteristics of BCR‐CDR3 repertoire in COVID‐19 patients and SARS‐CoV‐2 vaccinated volunteers
Xiao, J., Luo, Y. Q., Li, Y., & Yao, X. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29488 · Cited by 6
“15,16 Innate immunity may play a significant role in mild or asymptomatic infection; 17 its failure and/or acquired immunity development would cause pathological damage to the severe infection individual.”
Background
Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak
Maciorowski, D., Ogaugwu, C., Durvasula, S. R., Durvasula, R. V., & Kunamneni, A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220979579 · Cited by 6
The Neutralizing Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 and the Cytokine/Chemokine Release in Patients with Different Levels of Coronavirus Diseases 2019 Severity: Cytokine Storm Still Persists Despite Viral Disappearance in Critical Patients
Tjan, L. H., Nagano, T., Furukawa, K., Nishimura, M., Arii, J., Fujinaka, S., Iwata, S., Sano, S., Tohma, Y., Nishimura, Y., et al. (2021) · JMA Journal · doi:10.31662/jmaj.2020-0083 · Cited by 6
“Similarly, it has been reported that the neutralizing antibody titer detected in a young man with mild SARS-CoV-2 infection rapidly increased from day 4 until day 20 ((22)).”
Background
Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
Focosi, D., Maggi, F., Franchini, M., Aguzzi, A., Lanza, M., Mazzoni, A., & Menichetti, F. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.04.003 · Cited by 6
SARS-CoV-2 Epitopes following Infection and Vaccination Overlap Known Neutralizing Antibody Sites
Yang, L., Liang, T., Pierson, L. M., Wang, H., Fletcher, J. K., Wang, S., Bao, D., Zhang, L., Huang, Z. J., Zheng, W., et al. (2022) · Research · doi:10.34133/2022/9769803 · Cited by 7
Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants
Lunderberg, J. M., Dutta, S., Collier, A.-R. Y., Lee, J.-S., Hsu, Y., Wang, Q., Zheng, W., Hao, S., Zhang, H., Feng, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032574 · Cited by 7
SARS-CoV-2 receptor binding domain-specific antibodies activate platelets with features resembling the pathogenic antibodies in heparin-induced thrombocytopeniaPreprint
Zhu, W., Zheng, Y., Yu, M., Wei, J., Zhang, Y., Topchyan, P., Nguyen, C. P., Janecke, R., Kreuziger, L. B., White, G. C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-462080/v1 · Cited by 6
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395
Optical Detection of SARS-CoV-2 Utilizing Antigen-Antibody Binding Interactions
Ahmad, M. A., Mustafa, F., Panicker, N. G., & Rizvi, T. A. (2021) · Sensors · doi:10.3390/s21196596 · Cited by 5
Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection
Kumar, S., Dutta, D., Ravichandiran, V., & Sukla, S. (2022) · 3 Biotech · doi:10.1007/s13205-022-03281-5 · Cited by 5
How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?
Pons, S., Uhel, F., Frapy, E., Sérémé, Y., Zafrani, L., Aschard, H., & Skurnik, D. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10477-y · Cited by 6
“Only two antibodies seemed to efficiently neutralize the virus with the more potent directed against the RBD, suggesting that monoclonal antibodies targeting the RBD could be more efficient in preventing or treating SARS-CoV-2 infection [54].”
Background
RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers
Aguilar, R., Li, X., Crowell, C. S., Burrell, T., Vidal, M., Rubio, R., Jiménez, A., Hernández-Luis, P., Hofmann, D., Mijočević, H., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03165-22 · Cited by 5
“This is not surprising, as much of the immunodominant response associated with neutralization involves binding and/or blocking the S RBD to inhibit viral entry to host cells (12, 14).”
Background
In vitro measurements of protein–protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serumPreprint
Fiedler, S., Piziorska, M. A., Denninger, V., Morgunov, A., Ilsley, A., Malik, A. Y., Schneider, M. M., Devenish, S., Meisl, G., Aguzzi, A., et al. (2020) · bioRxiv · doi:10.1101/2020.12.20.422820 · Cited by 4
B Cell Receptor Repertoire Kinetics after SARS-CoV-2 Infection and VaccinationPreprint
Kotagiri, P., Mescia, F., Rae, W. M., Bergamaschi, L., Tuong, Z. K., Turner, L., Hunter, K., Gerber, F. P. P., Hosmillo, M. D. T., Hess, C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3910805 · Cited by 5
A subunit vaccine candidate based on the Spike protein of SARS-CoV-2 prevents infectious virus shedding in cats
Barroso‐Arévalo, S., Sánchez‐Morales, L., Domínguez, M., García‐Seco, T., Risalde, M. Á., García‐Bocanegra, I., Domı́nguez, L., & Sánchez‐Vizcaíno, J. M. (2022) · Research in Veterinary Science · doi:10.1016/j.rvsc.2022.05.003 · Cited by 4
Development of SARS‐CoV‐2 animal vaccines using a stable and efficient NDV expression system
He, L., Zhong, J., Li, G., Lin, Z., Zhao, P., Yang, C., Wang, H., Zhang, Y., Yang, X., & Wang, Z. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28237 · Cited by 4
“With the coordination of humoral and cellular immunity, antibodies, especially neutralizing antibodies, can be maintained for a long period according to several studies.(33,34) Memory B cells require T follicular helper cells to transmit signals to facilitate preferential”
Background
The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19
多賀谷, 悦., Kikuchi, K., Mitsuda, T., Ebihara, F., Maruyama, T., Hamada, Y., Kimura, T., Unagami, K., Kanzawa, T., Sekiguchi, H., et al. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101777 · Cited by 5
A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host
Minakshi, R., Jan, A. T., Rahman, S., & Kim, J. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.575404 · Cited by 4
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
Xiang, R., Wang, Y., Wang, L., Deng, X., Huo, S., Jiang, S., & Yu, F. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.12.015 · Cited by 4
Theoretical Explanation for the Rarity of Antibody-Dependent Enhancement of Infection (ADE) in COVID-19
Boldova, A. E., Korobkin, J.-J. D., Nechipurenko, Y. D., & Sveshnikova, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911364 · Cited by 4
Machine Learning Identifies Ponatinib as a Potent Inhibitor of SARS-CoV2-induced Cytokine StormPreprint
Chan, M., Vijay, S., McElrath, M. J., Holland, E. C., & Gujral, T. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.07.438871 · Cited by 4
Self-citation
Surface electrostatic shift on spike protein decreased antibody activities against SARS-CoV-2 Omicron variant
Yuan, S., Jiang, S., Zhang, Z., Fu, Y., Yang, X., Li, Z.-L., Hu, J., Du, J., Yuan, M., & Chen, Y. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.04.033 · Cited by 4

Authors: Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., Whaley, R. E., Singh, S., Boeckh, M., Cohen, K. W., McElrath, M. J., Englund, J. A., Chu, H. Y., Pancera, M., McGuire, A. T., & Stamatatos, L.
Affiliations: Fred Hutch Cancer Center (US)
University of Washington (US)
National Institutes of Health (US)
Corresponding author: Pancera, Marie
McGuire, Andrew T.
Stamatatos, Leonidas
ORCID: Seydoux, Emilie
Homad, Leah J.
MacCamy, Anna J.
Parks, K. Rachael
Hurlburt, Nicholas K.
Jennewein, Madeleine F.
Akins, Nicholas R.
Wan, Yu-Hsin
Feng, Junli
Whaley, Rachael E.
Singh, Suruchi
Boeckh, Michael
Cohen, Kristen W.
McElrath, M. Juliana
Englund, Janet A.
Chu, Helen Y.
Pancera, Marie
McGuire, Andrew T.
Stamatatos, Leonidas
Venue: Immunity
Publisher: Elsevier BV
Published: 2020-07
Volume: 53
Issue: 1
Pages: 98-105.e5
ISSN: 1074-7613 (ISSN-L)
DOI: 10.1016/j.immuni.2020.06.001
PMC: PMC7276322
OpenAlex: W3033450058
Cited by: 364
References: 44
Citations by year: 2026: 9 · 2025: 12 · 2024: 13 · 2023: 27 · 2022: 70 · 2021: 143 · 2020: 89
FWCI: 10.79
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 378 d)
Locations: Immunity (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Fred Hutchinson Cancer Research Center
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, spike protein, receptor binding domain, ACE2 receptor, somatic mutations, B-cell clonality, monoclonal antibodies, antibody epitope specificity, antibody affinity, antibody maturation, vaccine design
MeSH terms: Betacoronavirus, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Antibodies, Monoclonal, Antibodies, Viral, B-Lymphocytes, Binding Sites, Humans, Peptidyl-Dipeptidase A, Pneumonia, Viral, Protein Binding, Receptors, Virus, Viral Vaccines, Coronavirus Infections, Epitopes, B-Lymphocyte, Somatic Hypermutation, Immunoglobulin, Antibodies, Neutralizing, Pandemics, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks